Minervini SEPA — 8 Parameter Audit
| Parameter | Result | Data |
|---|---|---|
|
Price above 150 & 200 DMA
Minervini SEPA · Criterion 1
|
PASS | Price ₹474 · 150 DMA ₹473 · 200 DMA ₹471 |
|
150 DMA above 200 DMA
Minervini SEPA · Criterion 2
|
PASS | 150 DMA ₹473 vs 200 DMA ₹471 (+0.6%) |
|
200 DMA trending up ≥ 1 month
Minervini SEPA · Criterion 3
|
FAIL | 200 DMA slope: -0.43% over 4 weeks |
|
50 DMA above 150 & 200 DMA
Minervini SEPA · Criterion 4
|
PASS | 50 DMA ₹495 · 150 DMA ₹473 · 200 DMA ₹471 |
|
Price above 50 DMA
Minervini SEPA · Criterion 5
|
FAIL | Price ₹474 · 50 DMA ₹495 (-4.3%) |
|
Price within 25% of 52-week high
Minervini SEPA · Criterion 6
|
PASS | ₹474 vs 52W high ₹568 (-16.5%) |
|
Price ≥ 30% above 52-week low
Minervini SEPA · Criterion 7
|
FAIL | ₹474 vs 52W low ₹401 (+18.2%) |
|
RS Rating ≥ 70
Minervini SEPA · Criterion 8
|
FAIL | RS Rating: 60 (threshold: ≥70) |
Weinstein Stage Analysis
Base Stage 2
Advance Stage 3
Top Stage 4
Decline
AGARWALEYE.NS appears to be in Weinstein Stage 3 — the topping phase. The stock is losing momentum after an extended advance, with price action becoming erratic near the highs. Position traders applying strict methodology reduce or eliminate exposure during Stage 3.
Relative Strength Rating
Structural Analysis
Dr. Agarwal's Health Care Limited is currently trading 4.3% below its 50-day moving average, with Weinstein Stage 3 confirmed by the moving average hierarchy.
The Minervini SEPA audit finds 4 of 8 parameters confirmed. The parameter(s) not confirmed: 200 DMA trending up, Price above 50 DMA, 30% above 52W low, RS Rating ≥70.
Sanjaya's Reading
Mitra, main dekh raha hoon Dr. Agarwal's Health Care Limited ko — 4 criteria poore hain aath mein se.
Weinstein Stage 3 mein hai yeh instrument. अभी नहीं मित्र.
This is a static snapshot
This audit was generated from NSE closing data on 23 October 2026. Run a live audit with real-time data, animated criteria reveals, and Sanjaya's full narration.
Run a Live Audit — Free →Free tier includes Nifty 50 stocks · Pro unlocks full NSE universe
Frequently Asked Questions
AGARWALEYE (Dr. Agarwal's Health Care Limited) currently meets 4 of 8 Minervini SEPA parameters. AGARWALEYE currently meets 4 of 8 Minervini SEPA parameters. The parameter(s) not confirmed: 200 DMA trending up, Price above 50 DMA, 30% above 52W low, RS Rating ≥70.
AGARWALEYE is currently in Weinstein Stage 3. AGARWALEYE.NS appears to be in Weinstein Stage 3 — the topping phase. The stock is losing momentum after an extended advance, with price action becoming erratic near the highs. Position traders applying strict methodology reduce or eliminate exposure during Stage 3.
The Kasauti verdict for AGARWALEYE is अभी नहीं मित्र (Does Not Pass Yet). The Kasauti verdict for AGARWALEYE.NS is अभी नहीं मित्र — Does Not Pass Yet. With 4 of 8 criteria met, the primary area to monitor is: 200 DMA trending up, Price above 50 DMA, 30% above 52W low, RS Rating ≥70. This is a structural methodology assessment only — not a recommendation to deploy or exit capital. This is a structural methodology assessment only — not a recommendation to deploy or exit capital.